Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 30.00 | |
25 mg | In stock | $ 44.00 | |
50 mg | In stock | $ 61.00 | |
100 mg | In stock | $ 87.00 | |
200 mg | In stock | $ 127.00 | |
500 mg | In stock | $ 209.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 48.00 |
Description | Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control. |
Synonyms | ONO2235 |
Molecular Weight | 319.4 |
Formula | C15H13NO3S2 |
CAS No. | 82159-09-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9 mg/mL (28.18 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Epalrestat 82159-09-9 Endocrinology/Hormones Metabolism Reductase ONO2235 inhibit Aldose Reductase Inhibitor ONO 2235 ONO-2235 inhibitor